Press Releases
About Avicanna
Avicanna is a Canadian commercial-stage biopharmaceutical company established in research, development, and commercialization of evidence-based cannabinoid products for the global consumer, as well as medical and pharmaceutical market segments. Avicanna conducts its own R&D and collaborates with leading Canadian academic and medical institutions in Canada. Avicanna has established an industry leading scientific platform that includes R&D and clinical development and has led to the commercialization of over thirty proprietary products and robust pharmaceutical pipeline.
- MyMedi.ca Medical Cannabis Care: Medical Cannabis Pharmacy Platform Launched August 2023
- Medical Cannabis & Wellness: RHO Phyto TM
- Pharmaceutical Preparations and Pipeline
Feb. 13, 2024
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
TORONTO, February 13th, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce …
Feb. 05, 2024
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company
TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization…
Jan. 30, 2024
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil
TORONTO, January 30, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused …
Dec 4, 2023
Avicanna Announces Closing of Non-Brokered Private Placement
TORONTO, Dec. 04, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement
▪ Avicanna Reports Q3 2023 Results – November 14, 2023
▪ Avicanna Announces Appointment of Paul Fornazzari to Board of Directors – November 13, 2023
▪ Avicanna To Hold Third Quarter 2023 Earnings Conference Call – November 1, 2023
▪ Avicanna Provides Update on the Successful Launch of MyMedi.ca – October 11, 2023
▪ Retirement of Chandra Panchal, PhD from the Board of Directors – September 01, 2023
▪ Avicanna Reports Q2 2023 Financial Statement – August 15, 2023
▪ Avicanna Announces Closing of Acquisition and Launch of MyMedi.ca – August 1, 2023
▪ Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform – June 28 2023
▪ Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay – July 17 2023
▪ Avicanna Provides Corporate Update and Preliminary Q2 Results – June 28 2023
▪ Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets – June 26 2023
▪ Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”) – June 22 2023
▪ Avicanna and Langara College Announce Cannabinoid-Based Translational Research Collaboration and NSERC Grant – June 13, 2023
▪ Shoppers Drug Mart and Avicanna Execute Definitive Asset Purchase Agreement for Avicanna’s Acquisition of the Medical Cannabis by Shoppers Business – May 29, 2023
▪ Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate Update – May 17, 2023
▪ Avicanna Reports Q1 2023 Financial Statement – May 16, 2023
▪ Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca – May 4, 2023
▪ Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2022 – April 3, 2023
▪ Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers – March 28, 2023
▪ Avicanna Announces Closing of Non-Brokered Private Placement – March 21, 2023
▪ Avicanna Expands its Partnership with Viola Brands to the United Kingdom – February 07, 2023
▪ Avicanna Announces Warrant and Debenture Repricing and Amendments – January 30, 2023
▪ Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain – January 17, 2023
▪ Avicanna Announces Organizational Change in Avicanna LATAM S.A.S – December 30, 2022
▪ Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement – December 21 2022
▪ Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO PhytoTM CBG Transdermal Gel Topical Product– December 14 2022
▪ Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market – November 29, 2022
▪ Avicanna Reports Q3 2022 Financial Statement– November 14, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement – November 11, 2022
▪ Avicanna Announces Extension of Term Loan – October 31, 2022
▪ Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy – October 20, 2022
▪ Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals – October 18, 2022
▪ Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto – September 15, 2022
▪ Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto – September 15, 2022
▪ Avicanna Announces Results of Annual General and Special Meeting – September 01, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – August 17, 2022
▪ Avicanna Reports Q2 2022 Financial Statement – August 15, 2022
▪ Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals – July 20, 2022
▪ RE+PLAY ANNOUNCES THE NBPA AS AN OFFICIAL PARTNER – July 12, 2022
▪ Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders – July 11, 2022
▪ Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
▪ Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa – June 24, 2022
▪ Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
▪ Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa – June 24, 2022
▪ Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho – June 09, 2022
▪ Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho – May 24, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – May 12, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – May 6, 2022
▪ Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market – April 28, 2022
▪ Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company – April 28, 2022
▪ Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company – April 13, 2022
▪ Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG – April 5, 2022
▪ Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021 – March 31, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement – March 31, 2022
▪ Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma – February 10, 2022
▪ Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance – February 02, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units– January 28, 2022
▪ Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.– January 14, 2022
▪ Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel– January 10, 2022
▪ Avicanna Announces Changes to its Board of Directors– Jan. 4, 2022
▪ Avicanna Completes First Commercial Export of CBG from Colombia to Czech Republic– Dec. 24, 2021
▪ Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom– Dec. 22, 2021
▪ Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada– Dec. 20, 2021
▪ Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference– Dec. 10, 2021
▪ Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases– Dec. 06, 2021
▪ Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina– Nov. 30, 2021
▪ Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados– Nov. 25, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results– Nov. 12, 2021
▪ Avicanna Announces Resignation of Director– Nov. 11, 2021
▪ Viola Brands Launches Nationwide in Canada through the Medical Cannabis by ShoppersTM online platform– Nov. 9, 2021
▪ Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing– Nov. 8, 2021
▪ Avicanna Announces Management Change– Nov. 5, 2021
▪ Avicanna´s subsidiary obtains Good Agricultural and Collection Practices (“GACP”) Certification in Colombia– Nov. 4, 2021
▪ Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile– Oct. 22, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing– Oct. 19, 2021
▪ Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina– October 1, 2021
▪ Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy– Sept. 24, 2021
▪ Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador– Sept. 16, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update– Sept. 10, 2021
▪ Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020– Sept. 03, 2021
▪ Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil– Aug 27, 2021
▪ Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail Channels– Aug 24, 2021
▪ Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels– Aug 11, 2021
▪ Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis– July 28, 2021
▪ Avicanna Announces Change of Auditor– July 19, 2021
▪ Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization– June 29, 2021
▪ Avicanna Announces Results of Annual General Meeting and Provides Corporate Update– June 24, 2021
▪ Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels– June 15, 2021
▪ Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes– June 3, 2021
▪ Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021.– May 26, 2021
▪ Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital – May 6, 2021
▪ Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order – April 26, 2021
▪ Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update – April 12, 2021
▪ Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order – March 29, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $5.6 Million – Mar 4, 2021
▪ Avicanna Announces Exercise And Closing Of Over-Allotment Option – Dec 31, 2020
▪ Avicanna Announces Closing of Public Offering of Units – Dec 8, 2020
▪ Avicanna Announces Overnight Marketed Public Offering of Units – Nov 12, 2020
▪ Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – Nov 12, 2020
▪ Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – Aug 18, 2020
▪ Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
▪ Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
▪ Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
▪ Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
▪ Avicanna Closes First Tranche of Private Placement – January 24, 2020
▪ Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
▪ Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
▪ Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
▪ Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
▪ Avicanna Announces TSX Listing Date – July 16, 2019
▪ Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
▪ Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
▪ Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
▪ Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
▪ Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
▪ Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017